Results 201 to 210 of about 1,846,404 (321)

Poleward shift of subtropical highs drives Patagonian glacier mass loss. [PDF]

Nat Commun
Noël B, Lhermitte S, Wouters B, Fettweis X.   +3 more
europepmc   +1 more source

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats [PDF]

, 2011
Astrid Kamilla Stunes, Irene Westbroek, Björn Gustafsson, Reidar Fossmark, J.H. Waarsing, Erik Fink Eriksen, Christiane Petzold, Janne E. Reseland, Unni Syversen   +8 more
openalex   +1 more source

Diffusion Spectrum Imaging Maps Early Axonal Loss and a Unique Progressive Signal in Neuronal Intranuclear Inclusion Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To delineate specific in vivo white matter pathology in neuronal intranuclear inclusion disease (NIID) using diffusion spectrum imaging (DSI) and define its clinical relevance. Methods DSI was performed on 42 NIID patients and 38 matched controls.
Kaiyan Jiang, Yixiu Pei, Xiaobao Hu, Ying Xiong, Fang Wang, Yanyan Yu, Min Zhu, Dandan Tan, Meihong Zhou, Daojun Hong, Fuqing Zhou   +10 more
wiley   +1 more source

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review. [PDF]

J Diabetes
Wen J, Ansari U, Shehabat M, Ansari Z, Syed B, Razick A, Razick D, Akhtar M, Frezza E.   +8 more
europepmc   +1 more source

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

Butyrate Reducing Bone Mass Loss by Regulating the Expression of m6A Methyltransferase METTL3 in Implant-Associated Staphylococcus aureus Osteomyelitis. [PDF]

J Cell Mol Med
Sun C, Xu Y, Peng Z, Zhou X, Wang Z, Wan H, Yu B.   +6 more
europepmc   +1 more source

The mass-loss rates of red supergiants at low metallicity: detection of rotational CO emission from two red supergiants in the Large Magellanic Cloud [PDF]

, 2016
M. Matsuura, B. A. Sargent, B. M. Swinyard, J. Yates, P. Royer, M. J. Barlow, Martha L. Boyer, L. Decin, T. Khouri, M. Meixner, J. Th. van Loon, Paul Woods   +11 more
openalex   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Effectiveness of protein supplementation combined with resistance training to counteract disproportional fat-free mass loss following metabolic bariatric surgery: rationale and design of the ENRICHED randomised controlled trial. [PDF]

BMJ Open
de Roos BM, Yeh LY, van den Hooff PS, Nuijten MAH, Twisk JWR, Liem RSL, van Acker GJD, Severens JL, Kambic T, Serlie MJM, Monpellier VM, Eijsvogels TMH, Hopman MTE, Karregat JHM.   +13 more
europepmc   +1 more source

History of two mass loss processes in VY CMa. [PDF]

Proc Int Astron Union, 2023
Quintana-Lacaci G, Velilla L, Fonfría JP, Cernicharo J, Castro-Carrizo A, Agúndez M, Decin L.   +6 more
europepmc   +1 more source